Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (scIgG) (SCIGG-131)

Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD8 and anti-PSCA IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD8 & PSCA

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Prostate cancer

Targets

Target 1

CD8

Gene ID

925

UniProt ID

P01732

Alternative Names

CD8A; CD8a molecule; Cluster of differentiation 8; CD8; MAL; p32; Leu2

Target 2

PSCA

Gene ID

8000

UniProt ID

D3DWI6

Alternative Names

PSCA; prostate stem cell antigen; PRO232

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (scIgG) (SCIGG-131). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (scIgG) (CAT#: SCIGG-131)

Specifications

Targets

Customer Reviews and Q&As